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Destructive bone lesions occurring in patients who have previously had a malignancy are generally assumed to be a metastasis
from that malignancy. We reviewed 60 patients with a previous history of malignancy, who presented with a solitary bone lesion
that was subsequently found to be a new and diﬀerent primary sarcoma of bone. These second malignancies occurred in three
distinct groups of patients: (1) patients with original tumours well known to be associated with second malignancies (5%); (2)
patients whose second malignancies were likely to be due to the previous treatment of their primary malignancy (40%); (3)
patients in whom there was no clearly deﬁned association between malignancies (55%). The purpose of this study is to emphasise
the necessity for caution in assuming the diagnosis of a metastasis when a solitary bone lesion is identiﬁed following a prior
malignancy. Inappropriate biopsy and treatment of primary bone sarcomas compromises limb salvage surgery and can aﬀect
patient mortality.
Copyright © 2008 J. T. Patton et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
With the advances in the treatment of many cancers, patient
survival has improved dramatically such that a second
malignant neoplasm is now observed more frequently [1,
2]. It is well known that certain cancers are associated
with an increased risk of a second cancer [3, 4], and that
some treatments for cancer are in themselves known to be
aetiological agents in the pathogenesis of a second cancer
[5, 6]. It is commonly assumed that bone lesions occurring
in patients who have already had a malignant neoplasm are
metastases from that malignancy. If the lesions are multiple,
this will almost always be true, but if the lesion is solitary
then further investigation is necessary to exclude other
pathologies such as another primary bone tumour.
2. MATERIALS AND METHODS
The patients for this study were identiﬁed from a prospec-
tively recorded database. The records of 60 patients who
presented to our institution between 1980 and 2001 with
a primary bone tumour following a prior malignancy were
reviewed. The data was analysed in three separate groups,
although it should be pointed out that certain patients might
belong to more than one group.
Group1
Patients were categorised into this group if they had a
primary malignant neoplasm that is known to have a
strong relationship with the development of a secondary
malignancy.
Group2
This group included patients who had treatment of their
primary tumour that is known to predispose to the develop-
ment of secondary sarcoma. This includes all the radiation-
induced sarcomas that arose within the radiation ﬁeld.
Group3
Patients who developed a primary tumour of bone, subse-
quent to a diﬀerent primary malignant neoplasm that was2 Sarcoma
not clearly related to that neoplasm or to the treatment used
for that neoplasm, were included in this group.
3. RESULTS
At latest follow up, 31 patients (52%) within the study group
haddiedofdiseaserelatingtotheprimarybonesarcoma.The
average time to development of metastases was 17.6 months
(range 0–122 months).
Group1
This group consisted of three patients (5%), all of whom
had retinoblastoma as their ﬁrst tumour. The sarcoma that
subsequently developed was an osteosarcoma in two and a
primary leiomyosarcoma of bone in the other. The ages at
which the second tumour arose were ten, sixteen, and twenty
threeyears,withalagtimefromtheoriginaltumourofeight,
ﬁfteen, and twenty two years, respectively. All the second
tumourswerelocatedinsitesremotefromtheheadandneck.
Group2
There were twenty four patients (40%) who developed
a sarcoma following previous radiotherapy for a primary
tumour. Of these, twenty two were osteosarcoma and two
werehigh-gradesarcomawithnoidentiﬁablediﬀerentiation.
All of these secondary tumours were located in the previous
radiation ﬁeld. The average age of the patients at time of
diagnosis of the second tumour was 45 years (range 16–80
years) with a lag time from the initial tumour of 14 years
(range 4–31 years).
Group3
Thirty three patients (55%) developed a primary malignant
bone tumour following a previous malignancy that was not
felt to be clearly related to or associated with the treatment of
the ﬁrst malignancy (Table 1). The average age at diagnosis
of the second malignancy was 52 years (range 8–84 years)
and the lag time between tumours was 5 years (range 0–18
years). The most common initial malignancy was carcinoma
of the breast (thirteen patients), which was associated with
chondrosarcoma in six cases. Three patients presenting with
breast cancer developed bone sarcomas in the proximal limb
girdle. Only one of these patients received radiotherapy
as treatment for their breast cancer. The bone sarcoma in
this patient occurred in the contralateral proximal humerus.
Chondrosarcomawasthemostcommonsecondmalignancy,
aﬀecting twelve patients. The tumours occurred at a wide
distribution of sites, most frequently in the proximal femur
(eight patients). Three of the 33 patients presented with a
soft tissue sarcoma as the initial malignancy. The subsequent
primary bone tumours were located in sites remote from the
initial sarcoma and were felt to have histology unrelated to
the initial tumour.
4. DISCUSSION
Signiﬁcant progress has been made in the treatment of
and survival from numerous malignant neoplasms in recent
years. The improvement in patient survival has revealed
previously unrecognised sequelae. The second malignant
neoplasm is a well-described entity [1, 2]. It is becoming
clearer that genetic factors play a major role in the aetiol-
ogy of the second malignant neoplasm. These factors are
already well established in patients with tumours such as
retinoblastoma and Ewings sarcoma [4, 7]. In this study,
we have reported six cases of breast carcinoma associated
with chondrosarcoma. Recently, this association has been
reported by others and a genetic trait postulated [8]. It has
also been observed that cancer patients themselves are at
greater risk of developing a subsequent malignancy than the
general population [1].
Treatments for cancer have also been implicated in the
aetiology of a second malignant neoplasm. Radiotherapy is a
well-established causative agent and is dose dependent [6].
More recently, certain chemotherapeutic agents have also
been implicated [9].
There is a tendency to assume that a solitary bone
lesion following a malignancy is a metastasis from that
malignancy. This is especially true if the patient is over
40 [10], and the interval between the initial malignancy
and the second presentation is short. It was unfortunately
beyond the capability of this study to provide a denominator
of the number of patients with metastatic solitary bone
lesions from the same population that presented to our
tertiary referral centre with second and diﬀerent primary
bone tumours.
It is sobering to see that for the Group 3, patients in
this study the average interval between tumours was only
ﬁve years, and the average age of the patients was 52 years.
In patients who have had radiotherapy to a previous lesion
(Group 2), the assumption that the subsequent bone lesion
is recurrent disease from the ﬁrst malignancy can result in
incorrect or substandard therapy.
The potential deleterious eﬀects of a poorly performed
biopsy have been well described by Mankin et al. [11].
There are now several reports illustrating the disastrous
eﬀectsofinappropriatetreatmentofprimarybonesarcomas,
usually brought about by the assumption that the lesion is
a metastasis [12]. In this study, patients managed in our
tertiary referral centre had a biopsy prior to initial treatment.
However, we know of at least 3 cases where presumption
of the diagnosis of metastasis led to substandard treatment.
This was caused by the assumption that the lesion was a
metastasis, and the failure by the general orthopaedic sur-
geon to maintain an index of suspicion that a solitary bone
lesion could be a primary bone sarcoma. Whist no particular
traits were established, lesions in atypical sites (e.g., scapula,
ﬁbula) should be regarded with extrasuspicion. Most of
the lesions in this study had characteristic appearances of
primary bone sarcomas rather than metastases.
Internal ﬁxation of these lesions can spread tumour
cells along the whole length of the bone, rendering limbJ. T. Patton et al. 3
Table 1: Data for the Group 3 patients, in whom there was no clearly deﬁned association between malignancies.
Patient Age (at diagnosis of
second tumour) yrs Sex Second tumour (pri-
mary bone sarcoma)
Initial malignancy (Ca:
carcinoma)
Site of second
tumour
Lag (time to second
tumour) yrs
1 72 F Chondrosarcoma Ca breast Prox femur 14
2 59 F Chondrosarcoma Ca breast Prox humerus 1
3 50 F Chondrosarcoma Ca breast Prox femur 16
4 58 F Chondrosarcoma Ca breast Prox humerus 2
5 60 F Chondrosarcoma Ca breast Distal femur 0
6 60 F Chondrosarcoma Ca bronchus Prox tibia 2
7 72 F Chondrosarcoma Ca colon Distal femur 4
8 44 M Chondrosarcoma Ca oesophagus Pelvis 6
9 58 M Chondrosarcoma Ca rectum Prox tibia 7
10 82 M Chondrosarcoma Leukaemia Prox femur 6
11 52 F Chondrosarcoma Malignant melanoma Pelvis 3
12 66 F Chondrosarcoma Ca breast Metatarsal 0
13 66 F Chordoma Ca breast Sacrum 0
14 55 F Chordoma Ca breast Sacrum 12
15 29 F Ewings sarcoma Ca kidney Prox femur 0
16 12 F Ewings sarcoma Hodgkin’s lymphoma Fibula 6
17 9 M Ewings sarcoma Leukaemia Prox tibia 5
18 78 M Fibrosarcoma Malignantﬁbroushisti-
ocytoma (soft tisssue) Pelvis 2
19 41 F Fibrosarcoma Malignant melanoma Prox femur 3
20 84 F Leiomyosarcoma Ca breast Distal ﬁbula 8
21 47 F Malignant ﬁbrous
histiocytoma Hodgkin’s lymphoma Distal femur 6
22 39 M Malignant ﬁbrous
histiocytoma Seminoma Distal femur 10
23 27 F Malignant ﬁbrous
histiocytoma Ca breast Prox femur 2
24 66 M Osteosarcoma Ca bladder Scapula 3
25 63 F Osteosarcoma Ca breast Prox femur 5
26 10 M Osteosarcoma Hodgkin’s lymphoma Prox humerus 3
27 33 F Osteosarcoma Malignant melanoma Prox tibia 4
28 8 F Osteosarcoma Rhabdomyosarcoma Prox tibia 5
29 12 M Osteosarcoma Rhabdomyosarcoma Prox femur 11
30 81 F Sarcoma Ca breast Prox ﬁbula 0
31 72 F Sarcoma Ca breast Scapula 3
32 69 M Spindle cell sarcoma Ca prostate Scapula 1
33 81 F Spindle cell sarcoma Ca colon Prox tibia 18
salvage surgery impossible. Clearly, therefore, we would
urge caution in the treatment of solitary bone lesions, even
in the presence of previous malignancy. There is rarely
error in temporarily delaying potentially deleterious surgery
or radiotherapy, imaging the patient appropriately, and
performingabiopsybyasurgeonexperiencedinorthopaedic
oncological procedure [13].
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